

Proposed Listing of Claims
Do not enter in file – for use in discussion on telephone interview

1 – 62. (Cancelled)

63. (Previously Presented) A method of detecting a biological conditionneoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation in a subject, comprising determining whether the subject has an activating mutation in PDGFRA, and wherein the activating mutation comprises a variant nucleic acid sequence shown in one or more of positions 2072 through 2107 or 20902916 through 2937 of SEQ ID NO: 26.

64. (Previously Presented) The method of claim 63, wherein the activating mutation comprises a variant nucleic acid sequence shown in one or more of position 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2017 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24.

65. (Cancelled)

66. (Previously Presented) The method of claim [[65]]63, wherein the neoplasia comprises a gastrointestinal stromal tumor (GIST).

67. (Previously Presented) The method of claim 63, comprising:
reacting at least one PDGFRA molecule contained in a clinical sample from the subject with a reagent comprising a PDGFRA-specific binding agent to form a PDGFRA:agent complex.

68. (Previously Presented) The method of claim 67, wherein the PDGFRA molecule is a PDGFRA encoding nucleic acid or a PDGFRA protein.

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

69. (Currently Amended) The method of claim 67, wherein the ~~PDGFRA~~ PDGFRA-specific binding agent is a PDGFRA oligonucleotide or a PDGFRA ~~protein~~ protein-specific binding agent.

70. (Previously Presented) The method of claim 67, wherein the sample comprises a neoplastic cell or is prepared from a neoplastic cell.

71. (Currently Amended) The method of claim ~~63-67~~ wherein the PDGFRA molecule is a PDGFRA encoding nucleic acid sequence.

72. (Currently Amended) The method of claim 71, wherein the method comprises HPLC denaturation analysis of a PDGFRA ~~encoding~~ encoding nucleic acid molecule.

73. (Previously Presented) The method of claim 71, wherein the agent comprises a labeled nucleotide probe.

74. (Currently Amended) The method of claim 73, wherein the nucleotide probe has a sequence selected from the group consisting of:

(a) SEQ ID NO: 3, 5, 7, 9, 11, 20, 22, or 24; or
(b) fragments of (a) at least 15 nucleotides in length, and including the sequence shown in position(s) 2919 of SEQ ID NO: 3, 2917 and 2918 of SEQ ID NO: 5, 2927 and 2928 of SEQ ID NO: 7, 2075 to 2080 of SEQ ID NO: 9, 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2017 and 2072 of SEQ ID NO: 22, or 2916 to 2919 of SEQ ID NO: 24.

75. (Previously Presented) The method of claim 63, further comprising *in vitro* amplifying a PDGFRA nucleic acid prior to detecting the activating PDGFRA mutation.

76. (Previously Presented) The method of claim 75, wherein the PDGFRA nucleic acid is *in vitro* amplified using at least one oligonucleotide primer derived from a PDGFRA-protein encoding sequence.

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

77. (Previously Presented) The method of claim 76, wherein at least one oligonucleotide primer comprises at least 15 contiguous nucleotides from SEQ ID NO: 3, 5, 7, 9, 11, 20, 22, or 24.

78. (Currently Amended) The method of claim 76, wherein at least one oligonucleotide primer ~~comprises a sequence as represented by~~ at least 15 contiguous nucleotides in length and overlapping at least one sequence variant as shown in position(s) 2919 of SEQ ID NO: 3, 2917 and or 2918 of SEQ ID NO: 5, 2927 and or 2928 of SEQ ID NO: 7, any one of 2075 to 2080 of SEQ ID NO: 9, any one of 2089 to 2093 of SEQ ID NO: 11, 2076 of SEQ ID NO: 20, 2017 and or 2072 of SEQ ID NO: 22, or any one of 2916 to 2919 of SEQ ID NO: 24.

79. (Withdrawn) The method of claim 68, wherein the PDGFRA molecule is a PDGFRA protein.

80. (Withdrawn) The method of claim 79, wherein the complexes are detected by western blot assay.

81. (Withdrawn) The method of claim 79, wherein the complexes are detected by ELISA.

82. (Withdrawn) The method of claim 79, wherein the PDGFRA protein comprises a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 19, 12, 21, 23, and 25.

83. (Withdrawn) The method of claim 79, wherein the PDGFRA-specific binding agent is a PDGFRA-specific antibody or a functional fragment thereof.

84. (Withdrawn) The method of claim 83, wherein the agent is an antibody.

85. (Withdrawn) The method of claim 84, wherein the antibody is a monoclonal antibody.

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

86. (Withdrawn) The method of claim 85, wherein the monoclonal antibody recognizes an epitope of a variant PDGFRA and not an epitope of wildtype PDGFRA.

87. (Withdrawn) The method of claim 86, wherein the monoclonal antibody recognizes an epitope of a variant PDGFRA having the amino acid sequence as shown in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25.

88. (Withdrawn) The method of claim 83, wherein the antibody is reactive to an epitope including the amino acid sequence shown in position(s) 842 of SEQ ID NO: 4, 841 and 842 of SEQ ID NO: 6, 845 and 846 of SEQ ID NO: 8, 561 and 562 of SEQ ID NO: 10, 565 and 566 of SEQ ID NO: 12, 561 of SEQ ID NO: 21, 559 and 560 of SEQ ID NO: 23, or 841 and 842 of SEQ ID NO: 25.

89 - 115. (Cancelled)

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.